TOBAM’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $706K | Buy |
+4,190
| New | +$622K | 0.17% | 123 |
|
|
2026
Q1 | – | Sell |
-58
| Closed | -$8K | – | 274 |
|
|
2025
Q4 | $8K | Sell |
58
-4,983
| -99% | -$722K | ﹤0.01% | 255 |
|
|
2025
Q3 | $708K | Sell |
5,041
-4,543
| -47% | -$616K | 0.26% | 80 |
|
|
2025
Q2 | $1.21M | Sell |
9,584
-12,428
| -56% | -$1.43M | 0.47% | 57 |
|
|
2025
Q1 | $2.44M | Sell |
22,012
-9,256
| -30% | -$1.17M | 1.04% | 34 |
|
|
2024
Q4 | $4.27M | Sell |
31,268
-41,978
| -57% | -$5.19M | 1.3% | 27 |
|
|
2024
Q3 | $8.44M | Sell |
73,246
-17,219
| -19% | -$2.36M | 1.54% | 21 |
|
|
2024
Q2 | $12.5M | Sell |
90,465
-87,788
| -49% | -$12M | 1.95% | 17 |
|
|
2024
Q1 | $24.6M | Sell |
178,253
-48,588
| -21% | -$6.64M | 2.2% | 18 |
|
|
2023
Q4 | $29.9M | Sell |
226,841
-70,343
| -24% | -$8.1M | 2.61% | 9 |
|
|
2023
Q3 | $33.4M | Sell |
297,184
-14,531
| -5% | -$1.53M | 2.68% | 8 |
|
|
2023
Q2 | $29.4M | Sell |
311,715
-50,689
| -14% | -$4.95M | 2.22% | 15 |
|
|
2023
Q1 | $36.7M | Buy |
362,404
+74,564
| +26% | +$7.76M | 2.42% | 11 |
|
|
2022
Q4 | $34.4M | Buy |
287,840
+969
| +0.3% | +$113K | 2.28% | 13 |
|
|
2022
Q3 | $30.5M | Sell |
286,871
-19,623
| -6% | -$1.99M | 2.13% | 15 |
|
|
2022
Q2 | $29.9M | Buy |
306,494
+90,037
| +42% | +$8.31M | 1.87% | 19 |
|
|
2022
Q1 | $20.3M | Buy |
216,457
+24,704
| +13% | +$2.09M | 1.02% | 36 |
|
|
2021
Q4 | $16.3M | Buy |
191,753
+66,588
| +53% | +$6.13M | 0.73% | 51 |
|
|
2021
Q3 | $12M | Sell |
125,165
-49
| -0% | -$4.63K | 0.51% | 64 |
|
|
2021
Q2 | $12.2M | Buy |
125,214
+29,810
| +31% | +$2.86M | 0.49% | 65 |
|
|
2021
Q1 | $9.28M | Buy |
95,404
+35,249
| +59% | +$3.7M | 0.39% | 71 |
|
|
2020
Q4 | $5.77M | Buy |
60,155
+28,849
| +92% | +$2.79M | 0.26% | 85 |
|
|
2020
Q3 | $3.01M | Sell |
31,306
-23,350
| -43% | -$2.7M | 0.15% | 99 |
|
|
2020
Q2 | $6.67M | Sell |
54,656
-3,452
| -6% | -$381K | 0.43% | 62 |
|
|
2020
Q1 | $5.03M | Buy |
58,108
+36,315
| +167% | +$3.55M | 0.4% | 62 |
|
|
2019
Q4 | $2.34M | Buy |
21,793
+17,614
| +421% | +$1.84M | 0.14% | 82 |
|
|
2019
Q3 | $377K | Buy |
4,179
+529
| +14% | +$49.4K | 0.02% | 93 |
|
|
2019
Q2 | $308K | Buy |
3,650
+511
| +16% | +$42K | 0.02% | 95 |
|
|
2019
Q1 | $277K | Buy |
3,139
+1,369
| +77% | +$114K | 0.01% | 117 |
|
|
2018
Q4 | $126K | Buy |
+1,770
| New | +$170K | 0.01% | 143 |
|
Other funds holding NBIX
TOBAM's NBIX Position: Q2 2026 in Review
TOBAM opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 4,190 shares worth $706K. The stake represents 0.17% of the portfolio and ranks #123 among its holdings. This is a return to the name: TOBAM previously reported a position in NBIX as recently as Q4 2025.
TOBAM first reported a position in NBIX in Q4 2018 and has held it in 30 quarters since. The position peaked at $36.7M in Q1 2023. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- TOBAM held 4,190 shares of Neurocrine Biosciences worth $706K as of Q2 2026.
- Neurocrine Biosciences was a new TOBAM position in Q2 2026.
- Neurocrine Biosciences made up 0.17% of TOBAM's portfolio in Q2 2026, its #123 holding.
- TOBAM first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 30 quarters since.
- TOBAM's Neurocrine Biosciences position peaked at $36.7M in Q1 2023.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on TOBAM's 13F filing for Q2 2026, filed 31 Jul 2026.